Comparative Pharmacology
Head-to-head clinical analysis: BRINZOLAMIDE versus DARANIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRINZOLAMIDE versus DARANIDE.
BRINZOLAMIDE vs DARANIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brinzolamide is a carbonic anhydrase inhibitor. It inhibits carbonic anhydrase II (CA-II) in the ciliary processes of the eye, reducing aqueous humor secretion and thereby lowering intraocular pressure.
Carbonic anhydrase inhibitor. Inhibits carbonic anhydrase in the proximal renal tubule, reducing bicarbonate reabsorption and causing alkaline diuresis.
1 drop of 1% solution in the affected eye(s) twice daily.
50 mg orally once or twice daily; maximum 100 mg/day.
None Documented
None Documented
Terminal elimination half-life: 111 days (due to extensive red blood cell binding); clinical context: steady-state reached after 8–12 weeks of dosing
Clinical Note
moderateBrinzolamide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Brinzolamide."
Clinical Note
moderateBrinzolamide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Brinzolamide."
Clinical Note
moderateBrinzolamide + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Brinzolamide."
Clinical Note
moderateBrinzolamide + Fluconazole
Terminal elimination half-life: 2.5-3.5 hours (prolonged in renal impairment). Clinical context: Short half-life necessitates multiple daily dosing for sustained diuretic effect.
Renal: approximately 60% unchanged; biliary/fecal: minimal (<10%)
Renal: unchanged drug (approximately 50% of absorbed dose) and metabolites. Biliary/fecal: minimal.
Category A/B
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor
"The metabolism of Fluconazole can be decreased when combined with Brinzolamide."